⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
REGN News
Regeneron Pharmaceuticals Inc
REGN ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. (REGN) Investors to Pending Securities Class Action Amid Disclosures About Key Trial’s Protocol and Ultimate Failure
globenewswire.com
REGN
$REGN Shareholders: Suffer Losses When Regeneron Stock Plummeted 9%? Securities Fraud Class Action Deadline For Investors is September 14
accessnewswire.com
REGN
Amylin Analogs and Combination Therapies Clinical Trial Landscape Expands as 15+ Leading Companies Accelerate Drug Development | DelveInsight
globenewswire.com
AZN
LLY
NVO
PFE
AMGN
BMY
JNJ
REGN
VKTX
ZETA
CRSP
IONS
AXSM
MRK
GSK
SNY
IMUX
BMEA
ALKS
ALT
AARD
NOV
CARM
CRIS
LPCN
GILD
REG
SPRO
ABSI
ALZN
ANVS
BV
ARCL
ACIU
Contact Levi & Korsinsky by September 14, 2026 to Join Class Action Against Regeneron Pharmaceuticals, Inc. (REGN)
accessnewswire.com
REGN
September 14, 2026 Deadline: Join Class Action Lawsuit Against Regeneron Pharmaceuticals, Inc. (REGN) - Contact Levi & Korsinsky
accessnewswire.com
REGN
REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt
globenewswire.com
REGN
Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. (REGN) Shareholders of Class Action Lawsuit and September 14, 2026 Deadline
accessnewswire.com
REGN
Antibody Therapeutics Market worth $597.1 billion by 2035 - Exclusive Report by MarketsandMarkets™
prnewswire.com
ABBV
MRK
BMY
JNJ
AMGN
REGN
Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure - HBSS
prnewswire.com
REGN
REGN Shareholder Alert: September 14, 2026 Lead Plaintiff Deadline in Regeneron Pharmaceuticals, Inc. Securities Class Action - Contact The Gross Law Firm
prnewswire.com
REGN